Single-atom catalysts-based catalytic ROS clearance for efﬁcient psoriasis treatment and relapse prevention via restoring ESR1

Nature Communications, 2023 · DOI: 10.1038/s41467-023-42477-y · Published: October 27, 2023

Simple Explanation

Psoriasis, a common skin disease with a high recurrence rate, is linked to elevated levels of reactive oxygen species (ROS). This study introduces biomimetic iron single-atom catalysts (FeN4O2-SACs) capable of scavenging ROS. These catalysts mimic natural antioxidant enzymes, effectively reducing psoriasis-like symptoms and preventing relapse in experiments. The core mechanism involves the upregulation of estrogen receptor 1 (ESR1), a protein found to be reduced in psoriasis patients. This research suggests a new approach to psoriasis treatment, termed psoriasis catalytic therapy (PCT), inspired by multienzyme bionics (MIB), which offers a 'safe, effective, and long-term' therapeutic modality.

Study Duration

Not specified

Participants

Mice

Evidence Level

Not specified

Key Findings

1
FeN4O2-SACs exhibit multiple enzyme-mimicking activities, analogous to natural antioxidant enzymes, demonstrating broad-spectrum ROS scavenging capability.
2
In vitro and in vivo experiments demonstrate that FeN4O2-SACs effectively ameliorate psoriasis-like symptoms and prevent relapse, showing augmented efficacy compared to calcipotriol.
3
The upregulation of estrogen receptor 1 (ESR1) is identified as the core protein upregulated in psoriasis treatment through RNA sequencing and bioinformatic analysis.

Research Summary

This study introduces a 'psoriasis catalytic therapy' strategy using biomimetic materials (FeN4O2-SACs) to continuously scavenge overexpressed ROS, thereby ameliorating psoriatic lesions and preventing recurrence. FeN4O2-SACs effectively inhibit hyperproliferation and inflammatory infiltration in psoriasis by ROS elimination, demonstrating superior efficacy compared to clinical calcipotriol in IMQ-induced psoriasis-like mouse models. Mechanistically, FeN4O2-SACs treatment inhibits ESR1 deficiency via ESR1 upregulation, leading to significant reductions in psoriasis recurrence, highlighting a promising therapeutic pathway.

Practical Implications

Therapeutic Modality

Psoriasis catalytic therapy (PCT) offers a novel therapeutic modality for psoriasis treatment and relapse prevention.

Drug Development

Multienzyme-inspired bionics (MIB) can guide the development of new drugs that mimic the function of multiple natural enzymes.

Clinical Application

FeN4O2-SACs demonstrate potential for clinical application due to their ability to effectively treat psoriasis-like symptoms and prevent relapse without significant side effects.

Study Limitations

1
The study focuses on mice, and further research is needed to validate these findings in human clinical trials.
2
The long-term effects and potential toxicity of FeN4O2-SACs require further investigation.
3
The precise mechanisms of ESR1 upregulation by FeN4O2-SACs need further elucidation.

Your Feedback

Was this summary helpful?

Back to Physiology